Medical/Pharmaceuticals

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...

2022-08-03 19:38 2580

Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investme...

2022-08-03 08:00 2343

GenKOre develops hypercompact base editing system

DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage: www.genkore.com ), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs) published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 22:44 2745

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...

2022-08-02 21:00 2833

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...

2022-08-02 20:50 3040

Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...

2022-08-02 20:39 2300

Chime Biologics Received Commercial Manufacturing License Indicating the Kick-off into the Era of Commercial Production

* GMP commercial manufacturing license authorized by the National Drug Regulatory Authority, demonstrating Chime Biologics' capabilities in large scale commercial production  * Only 18 months to help LEPU Biopharma to obtain the approval of Puyouheng ™  ina new drug application demonstrating "...

2022-08-02 20:15 1992

NEXTSTELLIS® oral contraceptive has been nominated for the 2022 prix galien usa award for best pharmaceutical agent

ADELAIDE, Australia, Aug. 2, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix GalienUSA Award for Best Pharmaceutical A...

2022-08-02 13:00 2632

"OpenDEL®3.0 - DRUG DISCOVERY PARTNER" webinar offered by HitGen and Endpoints News coming up on Thursday 4th August

CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be jointly held by HitGen Inc. and Endpoints News on Thursday 4th August, to present you with a high-quality DEL product with all DEL information sharing and technical support. Dr. Guansai Liu, Execut...

2022-08-01 22:00 2819

OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology

2022 is set to be a milestone year for OriCell who has been focusing on the field of cancer immunotherapy for more than seven years and is fully committed to becoming an innovative global drug developer. SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- OriCell Therapeutics (S...

2022-08-01 22:00 3510

New Immunotherapy Combination Study for Nasopharyngeal Cancer Demonstrates Effectiveness of Lunit AI as Predictive Aid in Treatment Outcome--Published in Clinical Cancer Research

* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence for Lunit SCOPE IO's ability to predict patient response. * Analysis indicates Immune-excluded Immune Phenotype acts as a resistance mechanism against combination immunotherapy, further supporting...

2022-08-01 21:00 2454

GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine

* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...

2022-08-01 21:00 3090

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical compa...

2022-08-01 20:00 2684

Meihua International Medical Technologies Co., Ltd. Reports 2021 Financial Year Results

YANGZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today reported its financial res...

2022-08-01 19:00 3221

Eccogene Announces US IND Approval for THRβ agonist ECC4703

SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerabilit...

2022-08-01 15:00 2462

Nippon Express (China) Opens New Healthcare Branch in Shanghai

- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...

2022-08-01 14:22 2185

Nippon Express (China) Opens New Healthcare Branch in Shanghai

- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...

2022-08-01 14:17 2215

HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update

* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division   * Operating income turned to profit compared to the last quarter, while investment to R&D continued in t...

2022-07-29 20:00 3702

HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial

SINGAPORE, July 29, 2022 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with the current ...

2022-07-29 19:00 2615

ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China

GUANGZHOU, China, July 29, 2022 /PRNewswire/ -- The inaugural ZAODX World Conference on Early Detection of Cancer ("the Conference") was successfully held at the Chimelong International Conference Center inGuangzhou from July 15-17, 2022. In attendance were founders and representatives from over ...

2022-07-29 15:35 2066
1 ... 211212213214215216217 ... 261

Week's Top Stories